港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

寶濟藥業-B

92.150

-5.350-5.49%

成交量：56.65萬

成交額：5,586.70萬

市值：300.39億

市盈率：-11.95

高：102.000

開：97.550

低：92.150

收：97.500

52周最高：206.000

52周最低：56.000

股本：3.26億

香港流通股本：1.54億

量比：0.84

換手率：0.37%

股息：- -

股息率：- -

每股收益(LYR):-7.710

淨資產收益率：--

總資產收益率：--

市淨率：29.81

市盈率(LYR):-11.95

市銷率: 568.43

資料載入中...

總覽公司新聞資訊公告

異動解讀 | 新藥進展伴隨風險提示，寶濟藥業-B盤中大跌5.03%

寶濟藥業(02659.HK)KJ103用於腎移植脱敏治療III期臨床試驗完成隨訪將提交新藥上市申請

阿斯达克财经

寶濟藥業-B(02659)：KJ101新增適應症獲得臨床試驗批准

寶濟藥業-B：國家藥監局批准KJ101在中國開展胃黏液清除臨床試驗

寶濟藥業－Ｂ(02659)股價下跌5.042%，現價港幣$113.0

阿斯达克财经

寶濟藥業－Ｂ(02659)股價顯著下跌14.688%，現價港幣$136.5

阿斯达克财经

寶濟藥業-B（02659）2026年2月股份變動月報表，股本維持不變

寶濟藥業-B03月03日主力淨流入1289.8萬元散户資金拋售

寶濟藥業－Ｂ(02659)股價顯著波動14.526%，現價港幣$141.4

阿斯达克财经

寶濟藥業－Ｂ(02659)股價下跌5.048%，現價港幣$188.1

阿斯达克财经

寶濟藥業-B02月24日獲主力大幅加倉1.3億元

港股異動 | 寶濟藥業-B(02659)逆市升逾6%破頂獲納入恒生綜合指數 KJ017預計於26年首季度獲NDA批准

異動解讀 | 獲納入恒生綜合指數及產品進展利好，寶濟藥業-B盤中大漲6.09%

寶濟藥業-B創歷史新高

寶濟藥業－Ｂ(02659)股價上升5.154%，現價港幣$177.5

阿斯达克财经

寶濟藥業－Ｂ(02659)出現大手買入5萬股，成交價$167.0，涉資835萬

阿斯达克财经

寶濟藥業-B(02659)獲納入恒生綜合指數有望入選港股通開啓價值重估

【IPO追蹤】股價翻5倍，商業化剛起步：寶濟藥業的「甜蜜」能撐多久？

寶濟藥業-B02月12日主力淨流入3547.9萬元散户資金拋售

寶濟藥業-B創歷史新高

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02659/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02659","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"寶濟藥業-B","latestPrice":92.15,"timestamp":1774426110652,"preClose":97.5,"halted":0,"volume":566504,"delay":0,"changeRate":-0.05487179487179481,"floatShares":154000000,"shares":325981465,"eps":-7.710125888864562,"marketStatus":"未開盤","change":-5.35,"latestTime":"03-25 16:08:30","open":97.55,"high":102,"low":92.15,"amount":55866986,"amplitude":0.101026,"askPrice":93.4,"askSize":200,"bidPrice":92.15,"bidSize":8100,"shortable":0,"etf":0,"ttmEps":-1.4486026521134026,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774488600000},"marketStatusCode":0,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":97.5,"openAndCloseTimeList":[[1774402200000,1774411200000],[1774414800000,1774425600000]],"volumeRatio":0.844664,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","floatShares":154000000,"roa":"--","roe":"--","lyrEps":-7.710126,"volumeRatio":0.844664,"shares":325981465,"dividePrice":0,"high":102,"amplitude":0.101026,"preClose":97.5,"low":92.15,"week52Low":56,"pbRate":"29.81","psRate":"568.43","week52High":206,"institutionHeld":0,"latestPrice":92.15,"committee":0.951807,"eps":-7.710125888864562,"divideRate":0,"volume":566504,"delay":0,"ttmEps":-1.4486026521134026,"open":97.55,"prevYearClose":77.55,"prevWeekClose":93.65,"prevMonthClose":154.9,"prevQuarterClose":77.55,"fiveDayClose":90.3,"twentyDayClose":198.1,"sixtyDayClose":74.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02659\",params:#limit:5,,,undefined,":[{"date":"2026-03-26","symbol":"02659","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02659\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02659\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1769184000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02659\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02659","date":"2026-03-24","current":-63.613027,"percent":0.536232,"low":-150.791275,"twenty":-109.103806,"median":-74.885667,"eighty":-57.887882,"high":-20.527356,"avg":-80.08131,"sd":26.838716,"marketCap":31783192837},"quantilePoints":[{"date":"2025-12-12","current":-53.146224,"twenty":-53.348389,"median":-51.086695,"eighty":-37.627242,"marketCap":22280833132},{"date":"2025-12-19","current":-56.628418,"twenty":-56.115318,"median":-53.146224,"eighty":-50.330094,"marketCap":23796646945},{"date":"2025-12-24","current":-60.667186,"twenty":-57.368285,"median":-54.841733,"eighty":-51.357726,"marketCap":25573245929},{"date":"2026-01-02","current":-53.689307,"twenty":-58.867149,"median":-56.13619,"eighty":-51.993778,"marketCap":22720908110},{"date":"2026-01-09","current":-60.663453,"twenty":-59.744205,"median":-56.240552,"eighty":-53.146224,"marketCap":25736236661},{"date":"2026-01-16","current":-77.814349,"twenty":-61.547088,"median":-57.565784,"eighty":-53.651638,"marketCap":33119716844},{"date":"2026-01-23","current":-76.125836,"twenty":-72.759479,"median":-58.867149,"eighty":-53.689307,"marketCap":32369959474},{"date":"2026-01-30","current":-79.366151,"twenty":-76.125836,"median":-60.665319,"eighty":-55.0155,"marketCap":33902072360},{"date":"2026-02-06","current":-84.493791,"twenty":-76.125836,"median":-61.547088,"eighty":-55.626475,"marketCap":36183942615},{"date":"2026-02-13","current":-126.016863,"twenty":-78.017279,"median":-67.830536,"eighty":-56.031828,"marketCap":54275913922},{"date":"2026-02-20","current":-138.174242,"twenty":-79.686668,"median":-71.167377,"eighty":-56.115318,"marketCap":59426421069},{"date":"2026-02-27","current":-116.132786,"twenty":-104.714701,"median":-73.426035,"eighty":-56.395698,"marketCap":50494528928},{"date":"2026-03-06","current":-76.640212,"twenty":-111.983375,"median":-74.892856,"eighty":-56.998352,"marketCap":33054520551},{"date":"2026-03-13","current":-75.987902,"twenty":-110.582832,"median":-75.36732,"eighty":-57.563278,"marketCap":32924127965},{"date":"2026-03-20","current":-70.725897,"twenty":-109.509649,"median":-74.892856,"eighty":-57.733099,"marketCap":30528164197},{"date":"2026-03-24","current":-73.605533,"twenty":-109.103806,"median":-74.885667,"eighty":-57.887882,"marketCap":31783192837}],"updateTime":1774454891120},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02659\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1149494313","title":"異動解讀 | 新藥進展伴隨風險提示，寶濟藥業-B盤中大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149494313","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149494313?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 16:01","pubTimestamp":1774425677,"startTime":"0","endTime":"0","summary":"宝济药业-B(02659)今日盘中股价大幅下挫5.03%，引发市场关注。消息面上，公司早间发布公告，宣布其核心在研新药KJ103用于肾移植脱敏治疗的III期临床试验已完成所有入组受试者的主要随访，并将尽快向国家药监局提交新药上市申请。KJ103是一款全球首创的低免疫原性创新重组免疫球蛋白G降解酶，此前已获得突破性治疗药物认定。然而，公司在同一公告中亦提示风险，明确指出无法保证KJ103最终能够成功开发或实现商业化，并提醒股东及潜在投资者在买卖公司股份时需审慎行事。市场分析认为，尽管新药研发取得阶段性进展，但商业化前景的不确定性引发了投资者的担忧，可能是导致股价盘中承压下跌的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"gpt_icon":0},{"id":"2622049491","title":"寶濟藥業(02659.HK)KJ103用於腎移植脱敏治療III期臨床試驗完成隨訪  將提交新藥上市申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2622049491","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622049491?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 12:21","pubTimestamp":1774412460,"startTime":"0","endTime":"0","summary":"宝济药业(02659.HK) 公布，KJ103作为脱敏疗法用于中国等待肾脏移植的高敏感患者的III期临床试验，已于今年3月20日完成所有入组受试者的主要试验随访。公司将尽快向国家药监局提交新药上市申请。KJ103是一款全球首创、低免疫原性创新重组免疫球蛋白G(IgG)降解酶，用于治疗由病理性IgG抗体驱动的多种免疫介导疾病及病症。(sl/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260126145024008_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260126145024008_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512250/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512250/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02659","BK1161"],"gpt_icon":0},{"id":"2618190458","title":"寶濟藥業-B(02659)：KJ101新增適應症獲得臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618190458","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618190458?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 12:19","pubTimestamp":1773289175,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B 发布公告，公司自主研发、中国领先的经由合成生物学开发的重组人糜蛋白酶KJ101，已获中国国家药监局批准，可在中国开展用于胃镜检查时溶解去除胃内黏液的临床试验。KJ101具有纯度高、无动物源病毒污染的风险及无致敏性等核心优势。针对烧伤、外伤、手术切口、压力性溃疡及糖尿病足溃疡等伤口愈合适应症，该公司已于2025年2月获得国家药监局对KJ101的IND批准，并于2025年7月启动了其II期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161"],"gpt_icon":0},{"id":"1195288141","title":"寶濟藥業-B：國家藥監局批准KJ101在中國開展胃黏液清除臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1195288141","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195288141?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 12:03","pubTimestamp":1773288218,"startTime":"0","endTime":"0","summary":"宝济药业-B宣布，其研发的创新药KJ101已获得中国国家药品监督管理局（NMPA）的临床试验批准，将在中国开展针对胃黏液清除的临床研究。这一进展标志着公司在消化系统疾病治疗领域迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"gpt_icon":0},{"id":"2618059989","title":"寶濟藥業－Ｂ(02659)股價下跌5.042%，現價港幣$113.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2618059989","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618059989?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 10:00","pubTimestamp":1773280800,"startTime":"0","endTime":"0","summary":"[下跌股]宝济药业－Ｂ(02659) 股价在上午10:00比前收市价下跌5.042%，现股价为港币$113.0。至目前为止，今日最高价为$121.4，而最低价为$113.0。总成交量为10.7万股，总成交金额为港币$1.256千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD260312494/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD260312494/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02659"],"gpt_icon":0},{"id":"2617504057","title":"寶濟藥業－Ｂ(02659)股價顯著下跌14.688%，現價港幣$136.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2617504057","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617504057?lang=zh_tw&edition=fundamental","pubTime":"2026-03-06 13:45","pubTimestamp":1772775900,"startTime":"0","endTime":"0","summary":"[下跌股]宝济药业－Ｂ(02659) 股价在下午01:45比前收市价显著下跌14.688%，现股价为港币$136.5。至目前为止，今日最高价为$164.8，而最低价为$136.5。总成交量为49.13万股，总成交金额为港币$7.324千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603062483/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603062483/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02659"],"gpt_icon":0},{"id":"1130402102","title":"寶濟藥業-B（02659）2026年2月股份變動月報表，股本維持不變","url":"https://stock-news.laohu8.com/highlight/detail?id=1130402102","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130402102?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 16:07","pubTimestamp":1772611626,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年3月4日发布截至2026年2月28日的股份变动月报表。公告显示，公司本月并无新增股份发行、购回或注销活动，股本保持稳定。公司注册股本方面，截至报告期末，普通股H股法定/注册股本仍为154,327,250股，面值每股人民币0.2元；普通股内资股法定/注册股本为171,654,215股，面值同为人民币0.2元。两项合计的注册股本约为人民币65,196,293元，与上月持平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"gpt_icon":0},{"id":"2616320203","title":"寶濟藥業-B03月03日主力淨流入1289.8萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2616320203","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616320203?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 16:16","pubTimestamp":1772525765,"startTime":"0","endTime":"0","summary":"03月03日, 宝济药业-B股价涨4.89%，报收154.40元，成交金额1.2亿元，换手率0.54%，振幅17.87%，量比0.99。宝济药业-B今日主力资金净流入1289.8万元，上一交易日主力净流出257.8万元。该股近5个交易日下跌23.16%，主力资金累计净流入4548.0万元；近20日主力资金累计净流入4.6亿元，其中净流入天数为10日。该股主力净额占比0.05%，港股市场排名112/2719。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162215a445bd53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162215a445bd53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02659"],"gpt_icon":0},{"id":"2616664388","title":"寶濟藥業－Ｂ(02659)股價顯著波動14.526%，現價港幣$141.4","url":"https://stock-news.laohu8.com/highlight/detail?id=2616664388","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616664388?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 14:25","pubTimestamp":1772432700,"startTime":"0","endTime":"0","summary":"[异动股]宝济药业－Ｂ(02659) 股价在下午02:25出现显著波动14.526%，现股价为港币$141.4，比前收市价下跌8.715%8.651%。至目前为止，今日最高价为$163.9，而最低价为$141.4。总成交量为35.65万股，总成交金额为港币$5.457千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150411171_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150411171_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAC260302118/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAC260302118/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02659"],"gpt_icon":0},{"id":"2614627850","title":"寶濟藥業－Ｂ(02659)股價下跌5.048%，現價港幣$188.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2614627850","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614627850?lang=zh_tw&edition=fundamental","pubTime":"2026-02-26 10:48","pubTimestamp":1772074080,"startTime":"0","endTime":"0","summary":"[下跌股]宝济药业－Ｂ(02659) 股价在上午10:48比前收市价下跌5.048%，现股价为港币$188.1。至目前为止，今日最高价为$204.0，而最低价为$188.1。总成交量为20.5万股，总成交金额为港币$4.027千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602262164/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602262164/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02659","BK1161"],"gpt_icon":0},{"id":"2614365729","title":"寶濟藥業-B02月24日獲主力大幅加倉1.3億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614365729","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614365729?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 16:15","pubTimestamp":1771920930,"startTime":"0","endTime":"0","summary":"02月24日, 宝济药业-B股价涨11.61%，报收199.90元，成交金额2.3亿元，换手率0.76%，振幅11.67%，量比1.05。宝济药业-B今日主力资金净流入1.3亿元，连续5日净流入，上一交易日主力净流入466.7万元。该股近5个交易日上涨34.27%，主力资金累计净流入4.2亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入4.1亿元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224161713a4c22268&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224161713a4c22268&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659","BK1161"],"gpt_icon":0},{"id":"2613594750","title":"港股異動 | 寶濟藥業-B(02659)逆市升逾6%破頂 獲納入恒生綜合指數 KJ017預計於26年首季度獲NDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613594750","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613594750?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 10:17","pubTimestamp":1771899424,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宝济药业-B逆市涨超6%，盘中高见190港元创新高，截至发稿，涨6.09%，报190港元，成交额2805.61万港元。　　消息面上，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中宝济药业-B获纳入恒生综合指数。其中，目前重组人透明质酸酶并无作为单药疗法在中国市场销售，KJ017预计于2026年首季获得NDA批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260224/32022808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4588","HSCI","VT","VXUS","BK1161","BK4585","02659"],"gpt_icon":0},{"id":"1163123370","title":"異動解讀 | 獲納入恒生綜合指數及產品進展利好，寶濟藥業-B盤中大漲6.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163123370","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163123370?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 09:50","pubTimestamp":1771897847,"startTime":"0","endTime":"0","summary":"宝济药业-B(02659)今日盘中大涨6.09%，股价创下新高，引起了市场的广泛关注。消息面上，恒生指数公司宣布宝济药业-B获纳入恒生综合指数，此次变动预计将使其有望纳入港股通，从而吸引更多资金流入，为公司带来新的发展契机。此外，公司核心产品重组人透明质酸酶KJ017预计于2026年首季度获得NDA批准，该产品是中国首款报产的重组人透明质酸酶，用于大容量皮下给药，市场前景广阔。西牛证券指出，公司已为即将商业化的产品订下明确的商业化模式及时间表，增强了投资者对其未来增长潜力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"gpt_icon":0},{"id":"2613887287","title":"寶濟藥業-B創歷史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2613887287","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613887287?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 10:31","pubTimestamp":1771813864,"startTime":"0","endTime":"0","summary":"格隆汇2月23日丨宝济药业-B(02659.HK)涨0.99%，报184.1000港元，股价创历史新高，总市值600.13亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223103110a7148cfc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223103110a7148cfc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659","BK1161"],"gpt_icon":0},{"id":"2612625874","title":"寶濟藥業－Ｂ(02659)股價上升5.154%，現價港幣$177.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2612625874","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612625874?lang=zh_tw&edition=fundamental","pubTime":"2026-02-20 10:34","pubTimestamp":1771554840,"startTime":"0","endTime":"0","summary":"[上升股]宝济药业－Ｂ(02659) 股价在上午10:34比前收市价上升5.154%，现股价为港币$177.5。至目前为止，今日最高价为$177.5，而最低价为$168.8。总成交量为33.04万股，总成交金额为港币$5.753千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2602201667/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2602201667/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02659","BK1161"],"gpt_icon":0},{"id":"2611170832","title":"寶濟藥業－Ｂ(02659)出現大手買入5萬股，成交價$167.0，涉資835萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2611170832","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611170832?lang=zh_tw&edition=fundamental","pubTime":"2026-02-16 10:39","pubTimestamp":1771209540,"startTime":"0","endTime":"0","summary":"[大手成交]宝济药业－Ｂ(02659)在上午10:39出现大手买入，成交量为5万，成交价为港币$167.0，涉资835万。至目前为止，股价升0.12%，今日最高价为$167.0，而最低价为$164.6，总成交量为22.39万股，总成交金额港币$3.737千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2602162965/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2602162965/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02659"],"gpt_icon":0},{"id":"2611658168","title":"寶濟藥業-B(02659)獲納入恒生綜合指數 有望入選港股通開啓價值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2611658168","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611658168?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 22:05","pubTimestamp":1770991530,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中宝济药业-B获纳入恒生综合指数。此次变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据LiveReport大数据预测，宝济药业有望借此机会纳入港股通，迎来发展新契机。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","02659","VT","BK4585","HSCI","BK4588","BK1161"],"gpt_icon":0},{"id":"2611385192","title":"【IPO追蹤】股價翻5倍，商業化剛起步：寶濟藥業的「甜蜜」能撐多久？","url":"https://stock-news.laohu8.com/highlight/detail?id=2611385192","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611385192?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 19:16","pubTimestamp":1770981405,"startTime":"0","endTime":"0","summary":"在2025年上半年4.20亿元的收入中，绝大部分来自一次性许可协议首付款，核心产品SJ02的商业化收入尚未形成规模，KJ017、KJ103仍处于审批或临床阶段，缺乏可持续的收入支撑。对于普通投资者而言，不应盲目追逐短期股价涨幅，而应重点关注公司三大核心指标：SJ02的商业化销售数据、KJ017的NDA审批进度、KJ103的III期临床结果。资本市场的狂欢终会回归理性，宝济药业的甜蜜能否延续，最终取决于其从“管线潜力”到“业绩兑现”的转化能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213193427a4a0a581&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213193427a4a0a581&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659","BK1161"],"gpt_icon":0},{"id":"2611864681","title":"寶濟藥業-B02月12日主力淨流入3547.9萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2611864681","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611864681?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 16:15","pubTimestamp":1770884148,"startTime":"0","endTime":"0","summary":"02月12日, 宝济药业-B股价涨2.62%，报收148.80元，成交金额1.2亿元，换手率0.52%，振幅14.14%，量比0.82。宝济药业-B今日主力资金净流入3547.9万元，上一交易日主力净流出213.7万元。该股近5个交易日上涨51.68%，主力资金累计净流入3335.9万元；近20日主力资金累计净流入3543.8万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212162022a49b8f88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212162022a49b8f88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02659"],"gpt_icon":0},{"id":"2610115719","title":"寶濟藥業-B創歷史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2610115719","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610115719?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 09:43","pubTimestamp":1770860596,"startTime":"0","endTime":"0","summary":"格隆汇2月12日丨宝济药业-B(02659.HK)涨1.45%，报147.1000港元，股价创历史新高，总市值479.52亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212094423a6f11184&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212094423a6f11184&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02659"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":82,"code":"91000000","status":"200"}]}}